Article
Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
Blood - 18 Feb 2016
Wong Terrence N, Miller Christopher A, Klco Jeffery M, Petti Allegra, Demeter Ryan, Helton Nichole M, Li Tiandao, Fulton Robert S, Heath Sharon E, Mardis Elaine R, Westervelt Peter, DiPersio John F, Walter Matthew J, Welch John S, Graubert Timothy A, Wilson Richard K, Ley Timothy J, Link Daniel C
Abstract excerpt
There is interest in using leukemia-gene panels and next-generation sequencing to assess acute myelogenous leukemia (AML) response to induction chemotherapy. Studies have shown that patients with AML in morphologic remission may continue to have clonal hematopoiesis with populations closely related to the founding AML clone and that this confers an increased risk of relapse. However, it remains unknown how...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.